Pasar al contenido principal

ESTUDIO DE NUEVAS ESTRATEGIAS TERAPEUTICAS PARA SUPRIMIR LA RESISTENCIA A TERAPIAS BASADAS EN EL BLOQUEO DE LOS PUNTOS DE CONTROL INMUNITARIOS (ICB) EN CSCC Y HNSCC AVANZADOS

PID2020-113495RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

  • Lorenzo-Sanz, Laura|||0000-0001-6477-2163
  • Lopez-Cerda, Marta|||0000-0002-6511-0302
  • da Silva-Diz, Victoria
  • Artés, Marta H.
  • Llop, Sandra
  • Penin, Rosa M.
  • Bermejo, Josep Oriol|||0000-0002-8581-9415
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Esteller, M.|||0000-0003-4490-6093
  • Viñals, Francesc|||0000-0002-9918-6751
  • Espinosa, Enrique|||0000-0001-6562-7902
  • Oliva, Marc|||0000-0001-5352-8130
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Martín Liberal, Juan
  • Muñoz, Purificación|||0000-0002-3751-2099
Immune checkpoint blockade (ICB) approaches have changed the therapeutic landscape for many tumor types. However, half of cutaneous squamous cell carcinoma (cSCC) patients remain unresponsive or develop resistance. Here, we show that, during cSCC progression in male mice, cancer cells acquire epithelial/mesenchymal plasticity and change their immune checkpoint (IC) ligand profile according to their features, dictating the IC pathways involved in immune evasion. Epithelial cancer cells, through the PD-1/PD-L1 pathway, and mesenchymal cancer cells, through the CTLA-4/CD80 and TIGIT/CD155 pathways, differentially block antitumor immune responses and determine the response to ICB therapies. Accordingly, the anti-PD-L1/TIGIT combination is the most effective strategy for blocking the growth of cSCCs that contain both epithelial and mesenchymal cancer cells. The expression of E-cadherin/Vimentin/CD80/CD155 proteins in cSCC, HNSCC and melanoma patient samples predicts response to anti-PD-1/PD-L1 therapy. Collectively, our findings indicate that the selection of ICB therapies should take into account the epithelial/mesenchymal features of cancer cells.